ETH-LAD

ETH-LAD is an N6-ethyl derivative of LSD that emerged on the new psychoactive substances market, typically distributed on blotter paper. Analytical characterization via GC-MS, LC-MS, NMR, and IR spectroscopy has confirmed its identity and distinguished it from structural isomers such as EIPLA. In vitro metabolism studies show N-dealkylation and hydroxylation predominantly catalyzed by CYP1A2 and CYP3A4, with parent compounds or metabolites not reliably detected in rat urine using standard screening approaches. A 2016 Global Drug Survey analysis found LSD analogues including ETH-LAD had similar onset and duration to LSD but were rated lower in strength and pleasurable effects. A 2026 case report documented severe toxicity including acute aggression, unconsciousness, metabolic disturbances, and persistent psychosis requiring 17 days of hospitalization and psychiatric transfer, suggesting ETH-LAD may carry higher acute toxicity risk than LSD. Evidence remains limited to analytical characterization, self-report surveys, a single clinical case report, and preclinical animal data; no controlled human trials have been conducted.